#United States #New York #Class Action #Gross Law Firm #Novo Nordisk

Class Action Lawsuit Against Novo Nordisk A/S

The Gross Law Firm has initiated a call to action for shareholders of Novo Nordisk A/S (NYSE: NVO) amid allegations of misleading statements made by the company. Shareholders who acquired shares during the designated class period from May 7, 2025, through July 28, 2025, are encouraged to reach out for potential involvement in a class action lawsuit. The firm emphasizes that being a lead plaintiff is not a prerequisite to participate in the recovery process.

Background on Allegations

According to the allegations detailed in the complaint, Novo Nordisk's management made overly optimistic statements about the company's growth prospects. This was occurring alongside the dissemination of materially false and misleading information regarding its reported potential in the market. Specifically, the claim asserts that the company downplayed the negative impact of compound medications that allowed for personalized treatment options, overstated the likelihood that patients would switch to Novo’s branded medications, and misrepresented its capability to penetrate the GLP-1 market effectively.

The situation escalated on July 29, 2025, when Novo Nordisk announced its decision to decrease its sales and profit forecasts due to unexpectedly low growth projections for key products, Wegovy and Ozempic. This announcement came amidst increased competition and the continued reliance on compounded GLP-1s by healthcare providers. Following the news, Novo's stock price plummeted from $69.00 per share on July 28 to $53.94 on July 29, marking a dramatic decline of approximately 21.83% in one day.

Importance of Timely Action

Shareholders interested in joining the lawsuit must register their information before the September 30, 2025 deadline. The registration process will also enroll participants in a portfolio monitoring system, which provides updates regarding the case’s progress and their participation status. This step is critical for any investor who has faced losses due to the alleged false claims made by Novo Nordisk.

Why Choose Gross Law Firm?

The Gross Law Firm holds a strong reputation as a nationally recognized class action firm dedicated to protecting investor rights. Their primary focus is to advocate for individuals who have faced financial losses stemming from fraudulent practices and misleading corporate communications. Their mission extends to demanding accountability from companies and ensuring adherence to ethical business practices.

Next Steps for Interested Investors

To potentially participate in this class action lawsuit or to learn more about the allegations against Novo Nordisk, shareholders are encouraged to contact The Gross Law Firm at their office in New York or through their website. There is no upfront cost or obligation required to join the case, promoting accessible recourse for impacted shareholders.

Contact Information:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

The deadline for filing as a lead plaintiff is approaching swiftly. It is vital for shareholders to act promptly to secure their participation in this significant legal initiative against Novo Nordisk.